Market capitalization | $5.24m |
Enterprise Value | $1.15m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.31 |
Revenue growth (TTM) Revenue growth | -98.99% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-7.13m |
Free Cash Flow (TTM) Free Cash Flow | $-6.76m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Titan Pharmaceuticals, Inc.:
1 Analyst has issued a forecast Titan Pharmaceuticals, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.03 -0.03 |
114%
114%
|
|
EBITDA | -7.09 -7.09 |
15%
15%
|
EBIT (Operating Income) EBIT | -7.13 -7.13 |
17%
17%
|
Net Profit | -5.46 -5.46 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Gim Seow |
Employees | 4 |
Founded | 1992 |
Website | www.titanpharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.